Weak Trigger
now
Complete enrollment achieved for Phase 2 EVANGELINE trial of 'Endoxifen' for breast cancer; interim data confirms massive reduction in tumor cell proliferation Ki-67 markers.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |